4.3 Article

Transjugular liver biopsy and hepatic venous pressure gradient measurement in patients with and without liver cirrhosis

Journal

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
Volume 33, Issue 12, Pages 1582-1587

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MEG.0000000000001904

Keywords

transjugular liver biopsy; percutaneous liver biopsy; liver cirrhosis; hepatic venous pressure gradient; portal hypertension; acute liver failure

Ask authors/readers for more resources

The technical success and therapeutic decisions of TJLB are directly linked to the presence of absence of liver cirrhosis, with liver cirrhosis patients having lower rates of treatment initiation or adjustment based on TJLB results.
Background Transjugular liver biopsy (TJLB) and hepatic venous pressure gradient (HVPG) measurement are diagnostic procedures for patients with acute and chronic liver diseases. Technical execution of TJLB and HVPG may be challenging in patients with advanced liver disease. Objective We studied consecutive TJLB and HVPG procedures and investigated technical success, complications, quality of biopsies, indications and treatment changes in patients with and without liver cirrhosis. Methods In the study period from 2010 to 2018, 575 consecutive TJLB and HVPG procedures were analyzed. Demographic characteristics, procedure-related and follow-up data were extracted from medical records. Results In total, 259 (45%) patients were diagnosed with liver cirrhosis whereas 316 (55%) patients had no evidence of advanced chronic liver disease. Technical success of TJLB was significantly higher in patients without liver cirrhosis (287; 92%) compared to patients with liver cirrhosis [184; 76.7% (P=0.001)]. Technical success of HVPG measurement was not different between both groups (P=0.553). Liver biopsy specimens were significantly shorter in patients with liver cirrhosis (P=0.001). Medical therapy was adjusted in 163 (28.4%) patients. In patients with liver cirrhosis, results of TJLB led less frequently to therapy initiation or adjustment compared to patients without liver cirrhosis (P=0.001). In multivariate analysis, liver cirrhosis (Exp(B) 1.866; P=0.012), alanine aminotransferase (Exp(B) 0.248; P<0.001) and INR (Exp(B) 0.583; P= 0.027) were independently associated with treatment change. Conclusion Technical success and therapeutic decisions of TJLB are directly linked to presence or absence of liver cirrhosis. Copyright (C) 2020 Wolters Kluwer Health, Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available